Inflexion exits Pharmaspectra

Pharmaspectra's sale is Inflexion’s fourth to a US-listed buyer in the last 12 months.

  • Inflexion has announced nine exits in 2022 with a combined valuation of £2.5 billion
  • This deal marks Inflexion’s sixth exit in the healthcare and pharmaceutical services sector, generating an IRR of 25%
  • Inflexion completed the buyout of Pharmaspectra in 2019 via its enterprise fund

Inflexion announced on Monday that it has sold London-headquartered Pharmaspectra to a US-listed buyer. The deal is Inflexion’s fourth sale to a US-listed buyer in the last 12 months and its sixth exit overall in the healthcare and pharmaceutical sectors, generating an IRR of 25 percent.

Pharmaspectra owns the world’s largest continuously updated and integrated online repository of disseminated medical science information. The data sets are used across the pharmaceutical sector, with 13 of the top 20 pharmaceutical companies using Pharmaspectra’s services.

London-headquartered Inflexion is a middle-market private equity firm that backs  majority and minority investments. It typically looks to invest between £10 million to £400 million in equity in each deal. It was founded in 1999 and has £7.1 billion in assets under management.

“We are proud of the growth and development of Pharmaspectra during our stewardship,” said Simon Turner, managing partner at Inflexion. “The business has significantly increased its number of clients whilst enhancing its product offering through an ambitious programme of digital enhancement and international expansion, all contributing towards significant client wins.”

Inflexion has announced nine exits in 2022 with a combined valuation of £2.5 billion. During Inflexion’s ownership of Pharmaspectra, investment was made into the growth of its sales team, market and client services with the number of clients increasing by approximately 160 percent. Inflexion oversaw the launch of Pharmaspectra’s new product offering and technology platform. It also supported the international growth of the company including the build-out of a team in India and developing a market entry strategy into China.

“Pharmaspectra has seen significant growth over the past few years with the support of Inflexion,” said Jez Moulding, CEO of Pharmaspectra. “The business has invested in both its digital platform as well as its international operations, helping to attract a number of major new global clients.  I look forward to continuing our growth journey.”